- Tytuł:
- Expression of genes modulated by epigallocatechin-3-gallate in breast cancer cells
- Autorzy:
-
Bogacz, A.
Wolek, M.
Juskowiak, B.
Karasiewicz, M.
Kaminski, A.
Uzar, I.
Polaszewska, A.
Kostrzewa, Z.
Czerny, B. - Powiązania:
- https://bibliotekanauki.pl/articles/72469.pdf
- Data publikacji:
- 2018
- Wydawca:
- Instytut Włókien Naturalnych i Roślin Zielarskich
- Tematy:
-
gene expression
epigallocatechin-3-gallate
breast cancer
cancer cell
therapy - Opis:
- Breast cancer is the most common malignant cancer among women. Both drug resistance and metastasis are major problems in the treatment of breast cancer. Therefore, adjuvant therapy may improve patients’ survival and affect their quality of life. It is suggested that epigallocatechin gallate (EGCG) which is well known for its chemopreventive activity and acts on numerous molecular targets may inhibit the growth and metastasis of some cancers. Hence, discovering the metastatic molecular mechanisms for breast cancer may be useful for therapy.The aim of the study was to determine the effect of EGGC on the mRNA expression level of genes such as ZEB1, ABCB1, MDM2, TWIST1 and PTEN in MCF-7 breast cancer cells. MCF7/DOX were cultured in the presence of 0.2 μM DOX and EGCG (20-50 μM). The mRNA expression level was determined by real-time quantitative PCR using RealTime ready Custom Panel 96 kit. Our results showed an important increase (about 2-fold for 20 μM EGCG + 0.2 μM DOX and 2.5-fold for 50 μM EGCG + 0.2 μM DOX, p<0.05) in ZEB1 expression levels. In case of ABCB1 gene lack of influence on the mRNA level was observed (p>0.05). We also observed significant decrease of ZEB1 expression in MCF7 cells with 20 μM and 50 μM EGCG (p<0.05). In addition, EGCG (20 μM) caused an increase of MDM2 and PTEN mRNA levels in almost 100% (p<0.05) and 40% (p>0.05), respectively. Lack of the influence of EGCG was noted for the TWIST1 gene expression. In case of MCF7/DOX we showed an increase of mRNA level of PTEN gene about 50% (p<0.05). These results suggest that EGCG may be potentially used in adjuvant therapy in the breast cancer treatment.
- Źródło:
-
Herba Polonica; 2018, 64, 3
0018-0599 - Pojawia się w:
- Herba Polonica
- Dostawca treści:
- Biblioteka Nauki
Artykuł